Nabriva Therapeutics AG (NASDAQ: NBRV) is one of 198 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Nabriva Therapeutics AG to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and risk.

Profitability

This table compares Nabriva Therapeutics AG and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nabriva Therapeutics AG N/A -90.54% -72.82%
Nabriva Therapeutics AG Competitors -3,963.33% -117.93% -43.59%

Risk and Volatility

Nabriva Therapeutics AG has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics AG’s peers have a beta of 1.63, suggesting that their average share price is 63% more volatile than the S&P 500.

Institutional and Insider Ownership

50.3% of Nabriva Therapeutics AG shares are held by institutional investors. Comparatively, 46.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 2.8% of Nabriva Therapeutics AG shares are held by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Nabriva Therapeutics AG and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nabriva Therapeutics AG 0 0 7 0 3.00
Nabriva Therapeutics AG Competitors 482 2272 6206 120 2.66

Nabriva Therapeutics AG currently has a consensus price target of $20.14, suggesting a potential upside of 270.27%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.53%. Given Nabriva Therapeutics AG’s stronger consensus rating and higher possible upside, research analysts plainly believe Nabriva Therapeutics AG is more favorable than its peers.

Earnings and Valuation

This table compares Nabriva Therapeutics AG and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Nabriva Therapeutics AG $6.01 million -$59.30 million -2.22
Nabriva Therapeutics AG Competitors $207.79 million -$2.30 million 2.07

Nabriva Therapeutics AG’s peers have higher revenue and earnings than Nabriva Therapeutics AG. Nabriva Therapeutics AG is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Nabriva Therapeutics AG beats its peers on 7 of the 12 factors compared.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.